Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints
| Autor: | Irene Bocci, Malina Xiao, Kris Van Moer, Delphine Sauvage, Meriem Hasmim, Bassam Janji, Guy Berchem, Muhammad Zaeem Noman, Manon Bosseler, Audrey Lequeux, Elodie Viry |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_treatment Cell Plasticity Tumor cells CD47 Antigen Bioinformatics B7-H1 Antigen 03 medical and health sciences 0302 clinical medicine Immune system Antineoplastic Agents Immunological Cancer immunotherapy Neoplasms Tumor Microenvironment Medicine Animals Humans In patient Epithelial–mesenchymal transition Hypoxic tumor business.industry Hypoxia (medical) Immune checkpoint Cell Hypoxia 030104 developmental biology Oncology 030220 oncology & carcinogenesis medicine.symptom business |
| Zdroj: | Cancer letters. 458 |
| ISSN: | 1872-7980 |
| Popis: | Compared to traditional therapies, such as surgery, radio-chemotherapy, or targeted approaches, immunotherapies based on immune checkpoint blockers (ICBs) have revolutionized the treatment of cancer. Although ICBs have yielded long-lasting results and have improved patient survival, this success has been seriously challenged by clinical observations showing that only a small fraction of patients benefit from this revolutionary therapy and no benefit has been found in patients with highly aggressive tumors. Efforts are currently ongoing to identify factors that predict the response to ICB. Among the different predictive markers established so far, the expression levels of immune checkpoint genes have proven to be important biomarkers for informing treatment choices. Therefore, understanding the mechanisms involved in the regulation of immune checkpoints is a key element that will facilitate novel combination approaches and optimize patient outcome. In this review, we discuss the impact of hypoxia and tumor cell plasticity on immune checkpoint gene expression and provide insight into the therapeutic value of the EMT signature and the rationale for novel combination approaches to improve ICB therapy and maximize the benefits for patients with cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect